VISFO
Glossary

Glossary of terms

Resource of commonly used terms within the sector.

#

Addressable population

The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.

Addressable population

The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.

#

Artificial intelligence

Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.

Artificial intelligence

Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.

#

Asset evaluation

An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.

Asset evaluation

An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.

#

Bibliometric analysis

Bibliometric analysis is the application of statistical methods to the study of publication data.

Bibliometric analysis

Bibliometric analysis is the application of statistical methods to the study of publication data.

#

Biosimilar

A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.

Biosimilar

A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.

#

Clinical development

Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.

Clinical development

Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.

#

Clinical landscape

The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.

Clinical landscape

The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.

#

Clinical landscaping

Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.

Clinical landscaping

Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.

#

Competitive landscape

The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.

Competitive landscape

The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.

#

Competitive landscaping

Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.

Competitive landscaping

Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.

#

Conference landscape

The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.

Conference landscape

The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.

#

Conference landscaping

Conference landscaping is the systematic analysis of relevant scientific and medical meetings to identify key themes, trends, stakeholders, and strategic opportunities.

Conference landscaping

Conference landscaping is the systematic analysis of relevant scientific and medical meetings to identify key themes, trends, stakeholders, and strategic opportunities.

#

Conference planning

Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.

Conference planning

Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.

#

DOL impact factor

At VISFO, a Digital Opinion Leader (DOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank DOLs.

DOL impact factor

At VISFO, a Digital Opinion Leader (DOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank DOLs.

#

Development pipeline

A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.

Development pipeline

A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.

#

Digital Opinion Leader (DOL)

A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.

Digital Opinion Leader (DOL)

A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.

#

Digital activity

Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.

Digital activity

Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.

#

Digital landscape

The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.

Digital landscape

The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.

#

Digital landscaping

Digital landscaping is the structured analysis of online activity to identify key stakeholders, emerging trends, and scientific conversations within a therapeutic area.

Digital landscaping

Digital landscaping is the structured analysis of online activity to identify key stakeholders, emerging trends, and scientific conversations within a therapeutic area.

#

Digital listening

Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.

Digital listening

Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.

#

Digital transformation

Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.

Digital transformation

Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.

#

Disease burden

Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.

Disease burden

Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.

#

Epidemiology

Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.

Epidemiology

Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.

#

Evidence-generation program

An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.

Evidence-generation program

An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.

#

Feasibility planning

Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.

Feasibility planning

Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.

#

Generic

A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.

Generic

A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.

#

Health Economics and Outcomes Research (HEOR)

HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.

Health Economics and Outcomes Research (HEOR)

HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.

#

Health technology assessment (HTA)

A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.

Health technology assessment (HTA)

A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.

#

Incidence

In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.

Incidence

In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.

#

Indication

Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.

Indication

Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.

#

Indication assessment

An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.

Indication assessment

An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.

#

Insight

An insight is understanding derived from data or a lived experience that reveals a trend, need, or opportunity.

Insight

An insight is understanding derived from data or a lived experience that reveals a trend, need, or opportunity.

#

Intelligence board

An intelligence board is an expert-curated synthesis of evidence, data, and strategic insights designed to support pharmaceutical decision-making on specific questions or topics.

Intelligence board

An intelligence board is an expert-curated synthesis of evidence, data, and strategic insights designed to support pharmaceutical decision-making on specific questions or topics.

#

KCI impact factor

At VISFO, a Key Clinical Investigator (KCI) impact factor is a proprietary bibliometric-based calculation used to identify and rank KCIs.

KCI impact factor

At VISFO, a Key Clinical Investigator (KCI) impact factor is a proprietary bibliometric-based calculation used to identify and rank KCIs.

#

KOL impact factor

At VISFO, a Key Opinion Leader (KOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank KOLs.

KOL impact factor

At VISFO, a Key Opinion Leader (KOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank KOLs.

#

Key Clinical Investigator (KCI)

A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.

Key Clinical Investigator (KCI)

A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.

#

Key Opinion Leader (KOL)

A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.

Key Opinion Leader (KOL)

A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.

#

Launch sequence optimization

Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.

Launch sequence optimization

Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.

#

Market Access

Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.

Market Access

Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.

#

Market Access Key Opinion Leader (MAKOL)

A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.

Market Access Key Opinion Leader (MAKOL)

A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.

#

Market potential

Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.

Market potential

Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.

#

Market value

Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.

Market value

Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.

#

Medical Affairs

Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.

Medical Affairs

Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.

#

Medical Science Liaison (MSL)

A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.

Medical Science Liaison (MSL)

A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.

#

Mentions

Mentions are instances where a specific product, topic, company, or stakeholder is referenced in digital content such as social media posts, articles, webinars, or forums.

Mentions

Mentions are instances where a specific product, topic, company, or stakeholder is referenced in digital content such as social media posts, articles, webinars, or forums.

#

Modeling

Modeling is the process of using mathematical frameworks to simulate clinical, economic, or epidemiological scenarios to support pharmaceutical decision-making.

Modeling

Modeling is the process of using mathematical frameworks to simulate clinical, economic, or epidemiological scenarios to support pharmaceutical decision-making.

#

Morbidity rate

Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.

Morbidity rate

Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.

#

Mortality rate

Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.

Mortality rate

Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.

#

PIKOL impact factor

At VISFO, a Payer Influencing Key Opinion Leader (PIKOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank PIKOLs.

PIKOL impact factor

At VISFO, a Payer Influencing Key Opinion Leader (PIKOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank PIKOLs.

#

Payer Influencing Key Opinion Leader (PIKOL)

A Payer Influencing Key Opinion Leader (PIKOL) is a key influencer of healthcare policy and reimbursement decisions.

Payer Influencing Key Opinion Leader (PIKOL)

A Payer Influencing Key Opinion Leader (PIKOL) is a key influencer of healthcare policy and reimbursement decisions.

#

Pharmacovigilance

Pharmacovigilance is the science and practice of monitoring, detecting, assessing, and preventing adverse effects or other drug-related problems after a product has entered the market.

Pharmacovigilance

Pharmacovigilance is the science and practice of monitoring, detecting, assessing, and preventing adverse effects or other drug-related problems after a product has entered the market.

#

Prevalence

In epidemiology, prevalence describes the proportion of a population that has a disease at a specific point in time.

Prevalence

In epidemiology, prevalence describes the proportion of a population that has a disease at a specific point in time.

#

Price benchmarking

Price benchmarking is the process of comparing the price of a pharmaceutical product to similar therapies across markets to inform pricing strategy and negotiation.

Price benchmarking

Price benchmarking is the process of comparing the price of a pharmaceutical product to similar therapies across markets to inform pricing strategy and negotiation.

#

Price potential

Price potential refers to the estimated price a pharmaceutical product could reasonably achieve based on its clinical value, competitive positioning, and payer willingness to pay.

Price potential

Price potential refers to the estimated price a pharmaceutical product could reasonably achieve based on its clinical value, competitive positioning, and payer willingness to pay.

#

Pricing and reimbursement

Pricing and reimbursement refers to the processes by which a pharmaceutical product is assigned a price and granted coverage or funding by healthcare payers.

Pricing and reimbursement

Pricing and reimbursement refers to the processes by which a pharmaceutical product is assigned a price and granted coverage or funding by healthcare payers.

#

Product value communication

Product value communication is the strategic process of articulating the unique attributes, patient benefits, and economic value of a drug or therapy.

Product value communication

Product value communication is the strategic process of articulating the unique attributes, patient benefits, and economic value of a drug or therapy.

#

Publication strategy

A publication strategy is a structured plan for disseminating scientific and clinical data through peer-reviewed journals and congresses to support a product’s development and value story.

Publication strategy

A publication strategy is a structured plan for disseminating scientific and clinical data through peer-reviewed journals and congresses to support a product’s development and value story.

#

Real-world data (RWD)

Real-world data (RWD) refers to health-related data collected outside of traditional clinical trials, used to understand how treatments perform in routine clinical practice.

Real-world data (RWD)

Real-world data (RWD) refers to health-related data collected outside of traditional clinical trials, used to understand how treatments perform in routine clinical practice.

#

Real-world evidence (RWE)

Real-world evidence (RWE) refers to clinical insights derived from the analysis of real-world data (RWD), used to evaluate how treatments perform outside of controlled trial settings.

Real-world evidence (RWE)

Real-world evidence (RWE) refers to clinical insights derived from the analysis of real-world data (RWD), used to evaluate how treatments perform outside of controlled trial settings.

#

Research and development (R&D)

Research and development (R&D) is the process of discovering, designing, and testing new pharmaceutical products to advance medical science and improve patient outcomes.

Research and development (R&D)

Research and development (R&D) is the process of discovering, designing, and testing new pharmaceutical products to advance medical science and improve patient outcomes.

#

Rising Star

A Rising Star is a medical or scientific professional in the early to mid-stage of their career who demonstrates potential to become a prominent and influential voice in their field.

Rising Star

A Rising Star is a medical or scientific professional in the early to mid-stage of their career who demonstrates potential to become a prominent and influential voice in their field.

#

Rising Star impact factor

At VISFO, a Rising Star impact factor is a proprietary bibliometric-based calculation used to identify and rank future Key Opinion Leaders (KOLs).

Rising Star impact factor

At VISFO, a Rising Star impact factor is a proprietary bibliometric-based calculation used to identify and rank future Key Opinion Leaders (KOLs).

#

Risk factor

A risk factor is any attribute, condition, or behavior that increases the likelihood of developing a disease or experiencing an adverse health outcome.

Risk factor

A risk factor is any attribute, condition, or behavior that increases the likelihood of developing a disease or experiencing an adverse health outcome.

#

Stakeholder mapping

Stakeholder mapping is the creation of a comprehensive overview of key stakeholders relevant to a particular therapeutic area, indication, condition or product.

Stakeholder mapping

Stakeholder mapping is the creation of a comprehensive overview of key stakeholders relevant to a particular therapeutic area, indication, condition or product.

#

Trial site analysis

Trial site analysis is the evaluation of potential clinical trial sites to optimize study performance.

Trial site analysis

Trial site analysis is the evaluation of potential clinical trial sites to optimize study performance.